A novel approach combining oncolytic virotherapy and CAR T-cell technology, DISP-10, shows early promise in tackling challenging gastrointestinal malignancies.
Dispatch Bio has reached a significant milestone in its quest to develop innovative treatments for advanced gastrointestinal (GI) cancers. The company announced the dosing of the first participant in its groundbreaking Phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of its investigational immunotherapy, DISP-10. This first-in-human study marks a critical step forward in addressing the unmet medical needs of patients battling aggressive forms of GI cancers, including colorectal, gastric, oesophageal, and gastroesophageal adenocarcinomas.
The trial, a multicentre, open-label study, is meticulously designed to assess the multifaceted potential of DISP-10. Beyond its primary focus on safety and tolerability, the study aims to gather crucial preliminary data on the immunotherapy’s efficacy. The successful completion of the dose-limiting toxicity assessment by the first participant underscores the initial progress of this vital research. The US Food and Drug Administration (FDA) has recognized the potential of DISP-10 by granting it Fast Track designation for the treatment of advanced gastrointestinal cancers, a testament to its perceived ability to address a significant unmet need.
Unpacking the Novel Mechanism of DISP-10
At the heart of DISP-10 lies a sophisticated dual-component strategy designed to overcome the inherent complexities of treating solid tumours with immunotherapy. This innovative approach integrates two distinct but complementary therapeutic modalities: an oncolytic virus and a CAR T-cell therapy.
The first component, designated DV-10, is a meticulously engineered virus. Its primary function is to act as a delivery vehicle, introducing specific therapeutic agents directly into tumour cells. DV-10 is designed to deliver a modified B cell maturation antigen (BCMA), a target that has shown promise in certain hematologic malignancies, alongside potent immune-stimulating cytokines: Interleukin-18 (IL-18) and C-X-C motif chemokine ligand 9 (CXCL9). The strategic inclusion of these agents is intended to achieve a two-pronged effect: firstly, to directly modify tumour cells, making them more susceptible to immune attack, and secondly, to profoundly enhance the activity of T cells, the body’s primary cancer-fighting immune cells. This dual action aims to reprogram the tumour microenvironment, transforming it from an immunosuppressive shield into an inflammatory battleground for cancer cells.
The second cornerstone of DISP-10 is a chimeric antigen receptor (CAR) T-cell therapy developed by Bristol Myers Squibb. While this CAR T-cell therapy has received regulatory approval in the United States, its current indication is not for solid tumours. The integration of this established CAR T-cell technology within the DISP-10 framework, coupled with the targeted delivery mechanism of DV-10, suggests a synergistic approach designed to overcome the limitations previously associated with CAR T-cell therapy in the context of solid tumours. The rationale is that DV-10’s ability to modify the tumour and prime the immune system may create a more conducive environment for the CAR T-cells to effectively target and eliminate cancer cells.
A Chronological Journey Towards Clinical Advancement
The initiation of this Phase I clinical trial represents the culmination of extensive preclinical research and development efforts by Dispatch Bio. While specific timelines for the preclinical phase are not detailed in the provided information, the journey to a first-in-human trial typically involves rigorous laboratory studies, including in vitro experiments and animal models, to establish proof-of-concept, assess initial safety profiles, and identify potential therapeutic windows.
The subsequent progression to a Phase I trial signifies a crucial transition from laboratory bench to patient care. This phase is characterized by:
- First-in-Human Dosing: The administration of the investigational therapy to the initial human participant is a landmark event, marking the commencement of direct clinical evaluation.
- Dose-Limiting Toxicity (DLT) Assessment: A core objective of Phase I trials is to determine the maximum tolerated dose (MTD) of a new drug. This involves carefully monitoring participants for any severe or unexpected adverse events that might limit further dose escalation. The completion of this assessment for the first participant is a positive indicator, suggesting that the initial dose was tolerated within acceptable parameters.
- Safety and Tolerability Evaluation: Throughout the trial, comprehensive data will be collected on all adverse events, their severity, and their relationship to the investigational therapy. This forms the bedrock of understanding the drug’s safety profile.
- Preliminary Efficacy Assessment: While Phase I trials are primarily focused on safety, they also provide early insights into whether the therapy exhibits any signs of anti-tumour activity. This can be measured through various biomarkers, imaging studies, or clinical response assessments.
The multicentre nature of the study implies that the trial is being conducted at multiple clinical sites, which is crucial for recruiting a diverse patient population and accelerating the trial’s progress. The open-label design means that both the researchers and the participants are aware of the treatment being administered, allowing for direct observation and reporting of responses and side effects.
Supporting Data and the Urgent Need for Innovation
The urgency for novel therapeutic strategies in advanced GI cancers cannot be overstated. These malignancies represent a significant global health challenge, contributing to substantial morbidity and mortality. Colorectal cancer, in particular, has emerged as a critical concern, tragically becoming the primary cause of death in individuals under the age of 50. This statistic highlights a disturbing trend and underscores the pressing need for earlier detection and more effective treatment options, especially for younger patient populations who are often diagnosed at later stages.
The limitations of current immunotherapies in treating solid tumours are well-documented. These include:
- Lack of a Safe and Homogeneously Expressed Target Antigen: Unlike some blood cancers where target antigens are consistently present on cancer cells, solid tumours often exhibit heterogeneous antigen expression, meaning the target may not be present on all cancer cells. Furthermore, some potential targets might also be expressed on healthy tissues, leading to off-target toxicities.
- Narrow Therapeutic Window: The balance between achieving an effective anti-tumour response and managing dose-related toxicities can be precarious with many immunotherapies.
- Inhibitory Tumour Microenvironment: Solid tumours are adept at creating a microenvironment that suppresses the immune system, shielding themselves from immune attack. This includes the presence of immunosuppressive cells and molecules that actively hinder T-cell function.
Dispatch Bio’s DISP-10 is specifically engineered to address these multifaceted challenges. By combining oncolytic virotherapy with CAR T-cell technology and incorporating immune-boosting cytokines, the therapy aims to create a more potent and durable anti-tumour immune response. The delivery of IL-18 and CXCL9 by DV-10 is particularly noteworthy. IL-18 is a potent pro-inflammatory cytokine known to activate various immune cells, including natural killer (NK) cells and T cells, and can help overcome immune suppression. CXCL9 is a chemokine that attracts T cells, including cytotoxic T lymphocytes, to the tumour site, thereby enhancing immune cell infiltration.
The Fast Track designation granted by the FDA further validates the scientific rationale and potential clinical impact of DISP-10. This designation is intended to expedite the development and review of drugs that treat serious conditions and fill unmet medical needs, allowing for more frequent communication with the FDA throughout the development process and potentially leading to a rolling submission of the marketing application.
Official Responses and Expert Perspectives
The commencement of the DISP-10 trial has elicited positive reactions from key stakeholders within the company and the broader medical community.
Dr. Mauro Avanzi, Chief Medical Officer at Dispatch Bio, expressed his enthusiasm and optimism regarding the trial’s initiation: "Initiating this trial represents a meaningful step forward for patients with advanced GI cancers, reinforced by the FDA’s fast track designation for DISP-10." He elaborated on the significant hurdles that DISP-10 aims to overcome, stating, "We look forward to advancing this study as we work to overcome the longstanding limitations of treating solid tumours with immunotherapy, including lack of a safe and homogeneously expressed target antigen, a narrow therapeutic window, and an inhibitory tumour microenvironment." Dr. Avanzi’s statement highlights the company’s clear understanding of the therapeutic landscape and its strategic approach to addressing these critical challenges.
While not directly quoted in the provided text, the participation of multiple centres in the trial suggests collaboration with leading oncologists and research institutions. These clinical investigators play a vital role in patient recruitment, trial execution, and the meticulous collection of data, ensuring the scientific integrity and rigor of the study. Their expertise in treating advanced GI cancers will be instrumental in interpreting the findings and guiding future development of DISP-10.
The inclusion of Bristol Myers Squibb’s CAR T-cell therapy as a component of DISP-10 also signifies a potential collaboration or licensing agreement, underscoring the innovative nature of Dispatch Bio’s approach. This partnership leverages existing, approved technology while adapting it to a novel application in solid tumours.
Implications for the Future of GI Cancer Treatment
The successful advancement of DISP-10 through its Phase I trial could have profound implications for the treatment of advanced GI cancers. If the therapy demonstrates a favourable safety profile and compelling preliminary signs of efficacy, it could pave the way for a new class of immunotherapies capable of tackling previously intractable solid tumours.
For patients with advanced GI cancers: This trial offers a beacon of hope. The prospect of a novel treatment that can overcome the limitations of current immunotherapies could translate into improved outcomes, longer survival, and enhanced quality of life. The Fast Track designation suggests a potential for accelerated regulatory approval if the trial results are positive, meaning patients could gain access to this potentially life-saving therapy sooner.
For the field of cancer immunotherapy: The success of DISP-10 could validate the combination of oncolytic virotherapy and CAR T-cell therapy as a powerful strategy for treating solid tumours. This could inspire further research and development in similar combinatorial approaches, leading to a paradigm shift in how various solid tumours are treated. The ability to engineer oncolytic viruses to deliver specific therapeutic payloads and modulate the tumour microenvironment opens up a vast landscape of possibilities for future cancer therapies.
For Dispatch Bio: The successful completion of this Phase I trial, coupled with positive data, would significantly de-risk the program and position Dispatch Bio as a key player in the competitive field of cancer immunotherapy. This could lead to further investment, strategic partnerships, and the potential for future regulatory approvals and commercialization.
In conclusion, the dosing of the first participant in the DISP-10 Phase I clinical trial marks a significant and promising development in the fight against advanced gastrointestinal cancers. Dispatch Bio’s innovative approach, combining cutting-edge oncolytic virotherapy with established CAR T-cell technology, addresses critical unmet needs and holds the potential to redefine treatment paradigms for these challenging diseases. The medical and scientific communities will be closely watching the progress of this trial, hopeful that DISP-10 will usher in a new era of effective immunotherapy for patients battling GI malignancies.
About the Author
